Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Utility of 18FDG-PET/CT for risk prediction in patients with R/R myeloma undergoing CAR-T therapy

Luis-Esteban Tamariz-Amador • 28 Sep 2023
IMS 2023
Multiple Myeloma CAR-T

Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, briefly discusses a study exploring the value of using 18FDG-PET/CT when treating patients with relapsed/refractory (R/R) multiple myeloma with CAR-T cells. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Luis-Esteban Tamariz-Amador

1:07
Highlights from the CAR-T Meeting 2024: gaining an insight into the stages of CAR-T development
Luis-Esteban Tamariz-Amador • 20 Feb 2024
1:46
The factors associated with poor outcomes following CAR-T in patients with myeloma
Luis-Esteban Tamariz-Amador • 20 Feb 2024
2:24
The prognostic value of 18FDG-PET/CT in patients with R/R multiple myeloma treated with CAR-T
Luis-Esteban Tamariz-Amador • 20 Feb 2024
1:50
The prognostic value of serum paraprotein response kinetics in transplant-eligible NDMM
Luis-Esteban Tamariz-Amador • 28 Sep 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals